infliximab treatment groups over time, but this did not reach statistical significance at 12 months, which may have been a reflection of restricted sample size in this unadjusted analysis.
← all excerpts
Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.
2
—
—
The sentences
Rates of treatment persistence analyzed in this study showed a trend for being higher in vedolizumab vs. infliximab treatment groups over time, but this did not reach statistical significance at 12 months, which may have been a reflection of restricted sample size in this unadjusted analysis.